Author

M. J. LaBonte

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Bardelli· 1 shared A. U. Lindner· 1 shared C. J. Scott· 1 shared C. Latimer· 1 shared C. W. D. Armstrong· 1 shared C. W. Ong· 1 shared C. Winnington· 1 shared D. Griffin· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bardelli

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.

H. Khawaja, R. Briggs, C. Latimer, M. Rassel, D. Griffin, L. Hanson, A. Bardelli, F. Di Nicolantonio, S. S. McDade, C. J. Scott, S. Lambe, M. Maurya, A. U. Lindner, J. H. M. Prehn, J. Sousa, , S. Van Schaeybroeck

This study identifies Bcl-xL as a mediator of resistance to KRASG12C inhibitors in colorectal cancer and shows that combining Bcl-xL inhibition with KRASG12C inhibition enhances apoptosis and reduces tumor growth.

bioRxiv · May 10, 2022Cancer Biology

Targeting CXCR1 and CXCR2 to overcome radiotherapy resistance in PTEN-deficient prostate carcinoma

C. W. D. Armstrong, J. A. Coulter, C. W. Ong, P. J. Maxwell, S. Walker, K. T. Butterworth, O. Lyubomska, S. Berlingeri, R. Gallagher, J. M. O'Sullivan, S. Jain, I. G. Mills, K. M. Prise, R. G. Bristow, M. J. LaBonte, D. J. J. Waugh

This study identifies PTEN-deficiency-associated CXC-chemokine signaling as a driver of radiotherapy resistance in prostate cancer and shows that targeting CXCR1/2 improves radiotherapy outcomes.

bioRxiv · Mar 16, 2020 · PreprintCancer Biology